Man Group’s BioXcel Therapeutics BTAI Stock Holding History

Man Group’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-96,473	Closed	-$129K	–	2356
2026 Q1	$129K	Buy	96,473 +39,648	+70%	+$65.3K	﹤0.01%	2339
2025 Q4	$90.9K	Buy	+56,825	New	+$117K	﹤0.01%	2207

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group's BTAI Position: Q2 2026 in Review

Man Group sold out of BioXcel Therapeutics (BTAI) in Q2 2026, closing a stake of 96,473 shares — an estimated $129K sold.

Man Group first reported a position in BTAI in Q4 2025 and held it in 2 quarters. The position peaked at $129K in Q1 2026. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Man Group reported no remaining BioXcel Therapeutics position as of Q2 2026 after selling out during the quarter.
Man Group sold 96,473 BioXcel Therapeutics shares in Q2 2026, an estimated $129K.
Man Group first reported a position in BioXcel Therapeutics in Q4 2025 and held it in 2 quarters.
Man Group's BioXcel Therapeutics position peaked at $129K in Q1 2026.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.